European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - drotrecogin alfa (activated) - sepsis; multiple organ failure - antithrombotic agents - xigris is indicated for the treatment of adult patients with severe sepsis with multiple organ failure when added to best standard care. the use of xigris should be considered mainly in situations when therapy can be started within 24 hours after the onset of organ failure (for further information see section 5.1).

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - insulin glargine - diabetes mellitus - drugs used in diabetes - treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - tadalafil - hypertension, pulmonary - urologicals - adultstreatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity (see section 5.1).efficacy has been shown in idiopathic pah (ipah) and in pah related to collagen vascular disease.paediatric populationtreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (pah) classified as who functional class ii and iii.

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - pemetrexed - mesothelioma; carcinoma, non-small-cell lung - antineoplastic agents - malignant pleural mesotheliomaalimta in combination with cisplatin is indicated for the treatment of chemotherapy-naïve patients with unresectable malignant pleural mesothelioma.non-small-cell lung canceralimta in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - florbetapir (18f) - radionuclide imaging - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.amyvid is a radiopharmaceutical indicated for positron emission tomography (pet) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for alzheimer’s disease (ad) and other causes of cognitive impairment. amyvid should be used in conjunction with a clinical evaluation.a negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of ad.

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetine - diabetic neuropathies - psychoanaleptics, - treatment of diabetic peripheral neuropathic pain.ariclaim is indicated in adults.

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - tadalafil - erectile dysfunction - urologicals - treatment of erectile dysfunction.in order for tadalafil to be effective, sexual stimulation is required.cialis is not indicated for use by women.

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetine - anxiety disorders; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - treatment of major depressive disorder.treatment of diabetic peripheral neuropathic pain.treatment of generalised anxiety disorder.cymbalta is indicated in adults.

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - ramucirumab - stomach neoplasms - antineoplastic agents - gastric cancercyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.colorectal cancercyramza, in combination with folfiri (irinotecan, folinic acid, and 5‑fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.non-small cell lung cancercyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.hepatocellular carcinomacyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (afp) of ≥ 400 ng/ml and who have been previously treated with sorafenib.

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetine - neuralgia; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - duloxetine lilly is indicated in adults for:treatment of major depressive disordertreatment of diabetic peripheral neuropathic paintreatment of generalised anxiety disorderduloxetine lilly is indicated in adults.